Role of radiotherapy in the multimodal treatment of Ewing sarcoma family tumors

Yunseon Choi, Do Hoon Lim, Soo Hyun Lee, Chuhl Joo Lyu, Jung Ho Im, Yun Han Lee, Chang-Ok Suh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose The aim of this study was to evaluate the role of radiotherapy (RT) in the management of Ewing sarcoma family tumors (ESFT). Materials and Methods Retrospective analysis was performed on 91 patients with localized ESFT treated from 1988 to 2012. Primary tumor size was ≥ 8 cm in 33 patients. Surgery, RT, and combined surgery with RT were applied in 37, 15, and 33 patients, respectively. Results Median follow-up was 43.8 months. Forty-three patients (47.3%) showed recurrence or progressive disease. Twelve patients (13.2%) showed local failure after initial treatment. Thirty-nine patients (42.9%) experienced distant metastases. The 5-year overall survival (OS), progression-free survival, and local control (LC) were 60.5%, 58.2%, and 85.1%, respectively. According to treatment, 5-year LC was 64.8% with RT and 90.2% with combined surgery and RT (p=0.052). Prognostic factors for OS were tumor size (≥ 8 cm, p < 0.001) and surgical resection (p < 0.001). In large tumors (≥ 8 cm), combined surgery and RT produced better LC compared to RT (p=0.033). However, in smaller tumors (< 8 cm), RT without surgery resulted in a similar LC rate as RT with surgery (p=0.374). Conclusion RT used for patients with unfavorable risk factors resulted in worse outcome than for patients who received surgery. Smaller tumors could be controlled locally with chemotherapy and RT. For large tumors, combined surgery and RT is needed. Proper selection of local treatment modality, RT, surgery, or both is crucial in the management of ESFT.

Original languageEnglish
Pages (from-to)904-912
Number of pages9
JournalCancer Research and Treatment
Volume47
Issue number4
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Combined Modality Therapy
Ewing's Sarcoma
Radiotherapy
Neoplasms
Survival
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Choi, Yunseon ; Lim, Do Hoon ; Lee, Soo Hyun ; Lyu, Chuhl Joo ; Im, Jung Ho ; Lee, Yun Han ; Suh, Chang-Ok. / Role of radiotherapy in the multimodal treatment of Ewing sarcoma family tumors. In: Cancer Research and Treatment. 2015 ; Vol. 47, No. 4. pp. 904-912.
@article{90dcb93de0094c0c97b9ca038ee6f145,
title = "Role of radiotherapy in the multimodal treatment of Ewing sarcoma family tumors",
abstract = "Purpose The aim of this study was to evaluate the role of radiotherapy (RT) in the management of Ewing sarcoma family tumors (ESFT). Materials and Methods Retrospective analysis was performed on 91 patients with localized ESFT treated from 1988 to 2012. Primary tumor size was ≥ 8 cm in 33 patients. Surgery, RT, and combined surgery with RT were applied in 37, 15, and 33 patients, respectively. Results Median follow-up was 43.8 months. Forty-three patients (47.3{\%}) showed recurrence or progressive disease. Twelve patients (13.2{\%}) showed local failure after initial treatment. Thirty-nine patients (42.9{\%}) experienced distant metastases. The 5-year overall survival (OS), progression-free survival, and local control (LC) were 60.5{\%}, 58.2{\%}, and 85.1{\%}, respectively. According to treatment, 5-year LC was 64.8{\%} with RT and 90.2{\%} with combined surgery and RT (p=0.052). Prognostic factors for OS were tumor size (≥ 8 cm, p < 0.001) and surgical resection (p < 0.001). In large tumors (≥ 8 cm), combined surgery and RT produced better LC compared to RT (p=0.033). However, in smaller tumors (< 8 cm), RT without surgery resulted in a similar LC rate as RT with surgery (p=0.374). Conclusion RT used for patients with unfavorable risk factors resulted in worse outcome than for patients who received surgery. Smaller tumors could be controlled locally with chemotherapy and RT. For large tumors, combined surgery and RT is needed. Proper selection of local treatment modality, RT, surgery, or both is crucial in the management of ESFT.",
author = "Yunseon Choi and Lim, {Do Hoon} and Lee, {Soo Hyun} and Lyu, {Chuhl Joo} and Im, {Jung Ho} and Lee, {Yun Han} and Chang-Ok Suh",
year = "2015",
month = "1",
day = "1",
doi = "10.4143/crt.2014.158",
language = "English",
volume = "47",
pages = "904--912",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

Role of radiotherapy in the multimodal treatment of Ewing sarcoma family tumors. / Choi, Yunseon; Lim, Do Hoon; Lee, Soo Hyun; Lyu, Chuhl Joo; Im, Jung Ho; Lee, Yun Han; Suh, Chang-Ok.

In: Cancer Research and Treatment, Vol. 47, No. 4, 01.01.2015, p. 904-912.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of radiotherapy in the multimodal treatment of Ewing sarcoma family tumors

AU - Choi, Yunseon

AU - Lim, Do Hoon

AU - Lee, Soo Hyun

AU - Lyu, Chuhl Joo

AU - Im, Jung Ho

AU - Lee, Yun Han

AU - Suh, Chang-Ok

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose The aim of this study was to evaluate the role of radiotherapy (RT) in the management of Ewing sarcoma family tumors (ESFT). Materials and Methods Retrospective analysis was performed on 91 patients with localized ESFT treated from 1988 to 2012. Primary tumor size was ≥ 8 cm in 33 patients. Surgery, RT, and combined surgery with RT were applied in 37, 15, and 33 patients, respectively. Results Median follow-up was 43.8 months. Forty-three patients (47.3%) showed recurrence or progressive disease. Twelve patients (13.2%) showed local failure after initial treatment. Thirty-nine patients (42.9%) experienced distant metastases. The 5-year overall survival (OS), progression-free survival, and local control (LC) were 60.5%, 58.2%, and 85.1%, respectively. According to treatment, 5-year LC was 64.8% with RT and 90.2% with combined surgery and RT (p=0.052). Prognostic factors for OS were tumor size (≥ 8 cm, p < 0.001) and surgical resection (p < 0.001). In large tumors (≥ 8 cm), combined surgery and RT produced better LC compared to RT (p=0.033). However, in smaller tumors (< 8 cm), RT without surgery resulted in a similar LC rate as RT with surgery (p=0.374). Conclusion RT used for patients with unfavorable risk factors resulted in worse outcome than for patients who received surgery. Smaller tumors could be controlled locally with chemotherapy and RT. For large tumors, combined surgery and RT is needed. Proper selection of local treatment modality, RT, surgery, or both is crucial in the management of ESFT.

AB - Purpose The aim of this study was to evaluate the role of radiotherapy (RT) in the management of Ewing sarcoma family tumors (ESFT). Materials and Methods Retrospective analysis was performed on 91 patients with localized ESFT treated from 1988 to 2012. Primary tumor size was ≥ 8 cm in 33 patients. Surgery, RT, and combined surgery with RT were applied in 37, 15, and 33 patients, respectively. Results Median follow-up was 43.8 months. Forty-three patients (47.3%) showed recurrence or progressive disease. Twelve patients (13.2%) showed local failure after initial treatment. Thirty-nine patients (42.9%) experienced distant metastases. The 5-year overall survival (OS), progression-free survival, and local control (LC) were 60.5%, 58.2%, and 85.1%, respectively. According to treatment, 5-year LC was 64.8% with RT and 90.2% with combined surgery and RT (p=0.052). Prognostic factors for OS were tumor size (≥ 8 cm, p < 0.001) and surgical resection (p < 0.001). In large tumors (≥ 8 cm), combined surgery and RT produced better LC compared to RT (p=0.033). However, in smaller tumors (< 8 cm), RT without surgery resulted in a similar LC rate as RT with surgery (p=0.374). Conclusion RT used for patients with unfavorable risk factors resulted in worse outcome than for patients who received surgery. Smaller tumors could be controlled locally with chemotherapy and RT. For large tumors, combined surgery and RT is needed. Proper selection of local treatment modality, RT, surgery, or both is crucial in the management of ESFT.

UR - http://www.scopus.com/inward/record.url?scp=84931279304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931279304&partnerID=8YFLogxK

U2 - 10.4143/crt.2014.158

DO - 10.4143/crt.2014.158

M3 - Article

VL - 47

SP - 904

EP - 912

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -